Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

7.8K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
7.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.

Molecular therapy : the journal of the American Society of Gene Therapy·2006
Same author

Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model.

Journal of molecular medicine (Berlin, Germany)·2006
Same author

Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia.

Vascular medicine (London, England)·2005
Same author

Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.

Circulation·2005
Same author

Functional ephrin-B2 expression for promotive interaction between arterial and venous vessels in postnatal neovascularization.

Circulation·2005
Same author

Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor.

Circulation·2005

関連する実験動画

Updated: May 1, 2026

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

7.8K

心筋の遺伝子治療は,心筋の遺伝子治療である.

Jeffrey M Isner1

  • 1Department of Medicne, St. Elizabeth's Medical Center, Tufts School of Medicine, Boston, MA 02135, USA.

Nature
|January 24, 2002
PubMed
まとめ
この要約は機械生成です。

遺伝子療法は,冠動脈疾患や心不全などの心疾患に対する安全で効果的な治療法として有望であることが示されています. 臨床試験では,血管新生成長因子を使用することで,患者の機能改善の可能性のある利点が示唆されています.

さらに関連する動画

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.2K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.6K

関連する実験動画

Last Updated: May 1, 2026

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

7.8K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.2K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.6K

科学分野:

  • 心血管医学 心血管医学
  • 遺伝子療法の遺伝子治療法
  • 再生医学は,再生医療である.

背景:

  • 冠動脈疾患と心不全に対する従来の治療には限界があります.
  • 遺伝子療法は,心血管疾患に対する潜在的な代替案です.
  • 発心筋不全症と心不全は,未解決の重要な臨床的ニーズである.

研究 の 目的:

  • 心血管疾患に対する遺伝子療法の安全性と有効性を評価する.
  • 血管新生成長因子の潜在力を研究し,心筋不全症の治療に活用する.
  • 心不全に対する遺伝子療法の臨床前活性を評価する.

主な方法:

  • 安全性と効果を評価するために,第1相臨床試験が行われました.
  • 血管新生成長因子を活用した遺伝子治療が施されました.
  • 臨床前研究では,短期的な遺伝子発現を介して治療的血管新生を調査しました.

主要な成果:

  • ステージ1試験では,高安全性およびミオカルディアスイケミアの臨床効果が示されました.
  • 実験データは,心不全モデルにおける機能的改善を示唆している.
  • 治療的血管新生は,前臨床心不全研究において有望であることが示されています.

結論:

  • 遺伝子治療は冠動脈疾患と心不全の有効な代替手段です.
  • 血管新生成長因子遺伝子治療は,心筋不全症に対して安全で有益である.
  • 治療的な血管新生のための短期的な遺伝子発現は,心臓の機能を改善する可能性があります.